Patents by Inventor Robin R. Frey

Robin R. Frey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20240199745
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: July 10, 2023
    Publication date: June 20, 2024
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20240058450
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: May 31, 2022
    Publication date: February 22, 2024
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20200246460
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: September 6, 2019
    Publication date: August 6, 2020
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
    Publication number: 20200239553
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: November 6, 2019
    Publication date: July 30, 2020
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200002432
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 8, 2017
    Publication date: January 2, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20200002421
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: January 2, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur, George Doherty, Robin R. Frey, Xiaohong Song, Gerard M. Sullivan, Zhi-Fu Tao
  • ANTI-EGFR ANTIBODY DRUG CONJUGATES
    Publication number: 20190153107
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20190142941
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: January 4, 2019
    Publication date: May 16, 2019
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180193315
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1-Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: February 28, 2018
    Publication date: July 12, 2018
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • Bromodomain inhibitors
    Patent number: 9994581
    Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: June 12, 2018
    Assignee: AbbVie Inc.
    Inventors: Le Wang, Robin R. Frey, Todd M. Hansen, Dachun Liu, William J. McClellan, Keith F. McDaniel, John K. Pratt, Carol K. Wada
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20180071262
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: October 6, 2017
    Publication date: March 15, 2018
    Applicant: AbbVie Inc.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
    Patent number: 9796708
    Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 24, 2017
    Assignee: AbbVie Inc.
    Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iguturi, Madhu Babu Dabbeeru
  • BROMODOMAIN INHIBITORS
    Publication number: 20170015673
    Abstract: The present invention provides for compounds of formula (I) wherein Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, and A8, have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).
    Type: Application
    Filed: December 10, 2014
    Publication date: January 19, 2017
    Inventors: Le Wang, Robin R. Frey, Todd M. Hansen, Dachun Liu, William J. McClellan, Keith F. McDaniel, John K. Pratt, Carol K. Wada
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20160339117
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: December 9, 2015
    Publication date: November 24, 2016
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20160235716
    Abstract: Compounds having a structure of Formula (IX): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1- - - -Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 18, 2016
    Applicant: ABBVIE INC.
    Inventors: Edward A. Kesicki, Arthur F. Kluge, Michael A. Patane, John H. Van Drie, JR., Ce Wang, Maricel Torrent, Michael L. Curtin, Todd M. Hansen, Rick F. Clark, Robin R. Frey, Zhiqin Ji, Yujia Dai, William J. McClellan, Jane Gong, Gui-dong G. Zhu, Anthony Mastracchio, Michael R. Michaelides, Thomas D. Penning, Chunqiu C. Lai
  • BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same
    Publication number: 20160158377
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: December 9, 2015
    Publication date: June 9, 2016
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS
    Publication number: 20160060257
    Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicant: ABBVIE INC.
    Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iquturi, Madhu Babu Dabbeeru
  • Thienopyridine and furopyridine kinase inhibitors
    Patent number: 8273736
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: September 25, 2012
    Assignee: Abbott Laboratories
    Inventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
  • Thienopyridine and furopyridine kinase inhibitors
    Patent number: 7737160
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: June 15, 2010
    Assignee: Abbott Laboratories Inc.
    Inventors: Patrick Betschmann, Andrew F. Burchat, David J. Calderwood, Michael L. Curtin, Steven K. Davidsen, Heather M. Davis, Robin R. Frey, Howard R. Heyman, Gavin C. Hirst, Peter Hrnciar, Michael R. Michaelides, Melanie A. Muckey, Kelly D. Mullen, Paul Rafferty, Carol K. Wada
  • ISOINDOLINONE KINASE INHIBITORS
    Publication number: 20100076051
    Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.
    Type: Application
    Filed: November 25, 2009
    Publication date: March 25, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael L. Curtin, Steven K. Davidsen, Robin R. Frey, Howard R. Heyman, James H. Holms, Michael Michaelides, Douglas H. Steinman